Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Multiple solid tumors
Alectinib Shines on ALK Alterations in Advanced Solid Tumors including Children
In the TACKLE phase II trial in Japan, oral alectinib achieved a central-assessed ORR of 54.2% overall, with a median PFS of 24.9 months and OS of 38.8 months; responses were especially high in ALK fusions (76.5%…
- Trial result
Small cell lung cancer
ZL-1310, a DLL3-targeted ADC, achieves a 68% response rate in relapsed/refractory ES-SCLC
Treatment options are limited for patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) that progress after platinum-based chemotherapy (chemo). In a Phase I dose-escalation (n=28), ZL-1310, a DLL3…
- Trial result
Small cell lung cancer
ZG006 Ignites T‑Cell Response in Refractory SCLC by Targeting DLL3
ZG006 is a unique designed T cell engager, targeting CD3 and Delta-like ligand 3 (DLL3) on DLL3-expressing tumor cells such as small cell lung cancer (SCLC) or neuroendocrine carcinoma (NEC). In the phase 1 study…
- Trial result
Small cell lung cancer
DLL3-Targeted LB2102 CAR-T Demonstrates Dose-Dependent Expansion and Early Efficacy in SCLC/LCNEC
LB2102 is a CAR-T therapy engineered to target DLL3 and armored with a block TGF-β receptor blockade signals. This phase 1 study (NCT05680922) so far evaluated LB2102 in nine relapsed/refractory SCLC/LCNEC patients.…
NCT05680922 - Trial result
Neuroendocrine and adrenal tumors
Obrixtamig (DLL3/CD3 Engager) Achieves 40% ORR in DLL3-High Extrapulmonary NEC
Delta-like ligand 3 (DLL3) is highly expressed in neuroendocrine carcinomas (NEC). Obrixtamig (BI 764532) is a DLL3/CD3 IgG-like T-cell engager that targets DLL3-positive tumors. In a Phase I trial (NCT04429087),…
NCT04429087 - Trial result
Non-small cell lung cancer
Alectinib + Bevacizumab: A Dual-Targeted Strike but Cautionary Safety Against ALK-Rearranged NSCLC
This phase 2 trial (NCT03779191) with 41 patients combines alectinib with bevacizumab in advanced ALK-positive non-small cell lung cancer (NSCLC). The combination achieved a 12-month PFS rate of 97.1% (95% CI…
NCT03779191 - Trial result
Non-small cell lung cancer
Atezolizumab (anti–PD-L1) Combo in Non-Sq NSCLC: PFS Benefit Falls Short of Significance
The IMpower151 trial (NCT04194203) combined atezolizumab plus bevacizumab and chemotherapy for first-line metastatic non-squamous NSCLC for 305 patients in China. Patients in the ABCPem/Pac arm (atezolizumab,…
NCT04194203 - Trial result
Non-small cell lung cancer
BAY 2927088 Achieves ~59% ORR in Advanced HER2-Mutant NSCLC
BAY 2927088 is a potent, orally available, HER2 (ERBB2) reversible tyrosine kinase inhibitor (TKI). In the SOHO-01 Phase I/II trial (NCT05099172), patients with advanced NSCLC with HER2-activating mutations received…
NCT05099172 - Trial result
Non-small cell lung cancer
Zipalertinib Shows Sustained EGFR Exon 20 Inhibition, Yielding similar ORR to SOC in Pre-Treated NSCLC, but Better Tolerability.
Zipalertinib (zipa, CLN-081, TAS6417) is a novel EGFR TKI designed for NSCLC patients with EGFR exon 20 insertion (ex20ins) who progressed on platinum-based chemotherapy. In the phase 2b REZILIENT1 study of 176…
- Trial result
Non-small cell lung cancer
Afatinib Shines Against Chemo in Uncommon EGFR Mutant NSCLC in Japan
In this phase 3 trial in Japan (n=109, median follow‐up 33.6 months), EGFR Mutant NSCLC patients treated with afatinib had a higher median progression-free survival of 10.8 months compared to SoC platinum‐pemetrexed…
- Trial result
Non-small cell lung cancer
Sacituzumab Tirumotecan (TROP2 ADC) Delivers a 35.7% ORR in Uncommon EGFR-Mutated NSCLC
In a phase 2 study of 42 advanced NSCLC patients with uncommon EGFR mutations, sac-TMT achieved an objective response rate of 35.7%, a disease control rate of 85.7%, and a median progression-free survival of 9.5…
- Trial result
Head and neck cancer
PDL1V ADC Plus Pembrolizumab Achieves 50% ORR in PD-L1+ r/mHNSCC
In a phase 1 trial cohort of 14 PD-L1+ (CPS ≥1) patients with recurrent or metastatic HNSCC, the combination of PDL1V and pembrolizumab yielded a 50% ORR, including a 21.4% complete response rate. Common…
- Trial result
Head and neck cancer
Petosemtamab + Pembrolizumab: Dual EGFR & LGR5 Targeting Yields 60% ORR in PD-L1+ r/mHNSCC
In this Phase 2 trial, treatment of 43 evaluable r/m PD-L1+ HNSCC patients with petosemtamab 1500 mg Q2W plus pembrolizumab produced a 60% overall response rate (5 complete responses; 11%) and a median duration of…
NCT06525220 - Trial result
Head and neck cancer
Ficerafusp alfa (EGFR/TGF‑β) + Pembrolizumab Achieves 64% ORR in HPV‑Negative R/M HNSCC
In a Phase 1/1b expansion (N=42; 39 evaluable), the combination yielded a 54% ORR overall and 64% in HPV‑negative patients—with 21% achieving complete response—with durable responses (≥ 6 months in 72% overall and…
- Trial result
Head and neck cancer
Pembrolizumab (PD-1 inhibitor) in neoadjuvant/adjuvant setting extends event‐free survival in locally advanced HNSCC
In the Phase 3 KEYNOTE-689 study, pembrolizumab plus SOC increased median EFS from 26.9 to 59.7 months in the PD-L1 combined positive score (CPS) ≥ 10 group, and from 29.6 to 59.7 months in the CPS ≥ 1 group. The…
- Trial result
Breast cancer
PF-07248144, a first‐in‐class KAT6 inhibitor, achieves optimal 5 mg dose with fulvestrant in ER+/HER2– metastatic breast cancer
In phase 1 expansion, 5 mg PF-07248144 plus fulvestrant demonstrated an ORR of 37.2% (vs 24.1%) with a median duration of response of 15.8 months (vs 4.8 months at 1mg) and median PFS of 10.7 months (vs 3.6 months at…
- Trial result
Liver and bile duct cancer
Durvalumab + GemCis boosts 3-year survival in advanced biliary tract cancer (HR 0.74)
In the Phase III TOPAZ-1 study of patients with advanced biliary tract cancer, a combination of durvalumab and gem/cis resulted in a median OS of 12.9 months, compared to 11.3 months for the placebo with gem/cis,…
- Trial result
Sarcoma and GIST
Ripretinib (switch-control KIT/PDGFRA TKI) matches sunitinib on survival in second-line GIST
Phase 3 INTRIGUE (NCT03673501) randomized 453 imatinib-refractory GIST patients to continuous-dose ripretinib 150 mg vs intermittent sunitinib 50 mg (4 wk on/2 wk off); after 211 deaths, median OS was 35.5 mo vs 31.5…
NCT03673501 - Trial result
Prostate cancer
DB-1311/BNT324 (B7-H3 ADC) logs 28% responses and 8-mo rPFS in late-line CRPC
In the Phase 1/2 dose-optimization study NCT05914116, 65 heavily pre-treated metastatic CRPC patients (median 3 prior lines; 94% docetaxel, 15% Lu-177) received 6 mg/kg or 9 mg/kg Q3W DB-1311/BNT324; among 43…
NCT05914116 - Trial result
Prostate cancer
Tb-161 PSMA-I&T (β + Auger RLT) achieves 70% PSA50 response in post-taxane mCRPC
In the single-arm Phase I/II VIOLET trial (NCT05521412), 30 PSMA-PET–positive mCRPC patients previously treated with taxane ± ARPI received up to six Q6W cycles of [^161Tb]Tb-PSMA-I&T (4.4-7.4 GBq; 3 + 3 escalation);…
NCT05521412 - Trial result
Prostate cancer
Rucaparib (PARP inhibitor) maintenance after platinum induction hits 17.7 mo rPFS in BRCA-C (BRCA1/2 or PALB altered) mCRPC
In the single-arm Phase 2 trial NCT02985021, 18 HRR-deficient mCRPC patients received four 21-day cycles of docetaxel 60 mg/m² + carboplatin AUC5, then continuous rucaparib 600 mg BID; overall median rPFS was 8.1 mo,…
NCT02985021 - Trial result
Prostate cancer
Olaparib ± abiraterone (PARP-1/2 inhibitor) slashes rPFS risk by ≈ 75% in BRCA-mut mCRPC
Phase 3 data compiled in a new review show that olaparib monotherapy in PROfound’s Cohort A (BRCA1/2 ± ATM; n = 162 vs 83) cut radiographic PFS by 78% vs physician-choice ARPI (HR 0.22) and improved OS (HR 0.63); in…
- Trial result
Colorectal cancer
MK-1084 (KRAS G12C inhibitor) plus cetuximab drives 50% responses in advanced colorectal cancer
Phase 1 KANDLELIT-001 (NCT05067283) enrolled pre-treated KRAS G12C-mut CRC: 53 received MK-1084 monotherapy (ORR 36%), 34 got MK-1084 + cetuximab after ≥2 prior lines (ORR 50%), and 20 front-line patients received…
NCT05067283 - Trial result
Bladder and urothelial cancer
Avelumab (anti-PD-L1) plus ddMVAC nets 58% pCR pre-cystectomy and 87% 3-yr OS in muscle-invasive bladder cancer
Phase 2 AURA trial (NCT03674424) enrolled 137 non-metastatic MIBC patients slated for radical cystectomy: cisplatin-eligible cases got neoadjuvant avelumab with either ddMVAC (n = 38) or gem-cis (n = 36), while…
NCT03674424 - New trial
Multiple solid tumors
Phase 1/2a Trial of JAB-23E73 in Advanced KRAS-Altered Tumors
Jacobio is evaluating JAB-23E73—a small molecule KRAS inhibitor—in a multi-cohort study assessing safety, tolerability, pharmacokinetics, and preliminary antitumor activity in advanced solid tumors, including NSCLC,…
NCT06973564 - New trial
Multiple solid tumors
Phase 1 Trial of GEN1057 Targeting FAP alpha and DR4 in Advanced Solid Tumors
Genmab is conducting a first-in-human, open-label dose escalation study of GEN1057—a bispecific mAb targeting FAP alpha and DR4—to evaluate its safety and antitumor activity in patients with advanced or metastatic…
NCT06573294 - New trial
Multiple solid tumors
Augmented PET/CT Enhances Malignant Lesion Detection in Carcinoma
Washington University is evaluating AWSM-PET/CT—a technology designed to boost resolution and sensitivity—for improved detection of malignant lesions compared to standard FDG-PET/CT in carcinoma patients.
NCT05513027 - New trial
Non-small cell lung cancer
Phase II Trial of VEGFA-Targeted BNT327 with Docetaxel in Second-line Stage IV NSCLC
BioNTech SE is conducting a Phase II, multisite (Houston recruiting now), open-label, single-arm study evaluating the safety and efficacy of BNT327—a VEGFA-directed monoclonal antibody—in combination with docetaxel,…
NCT06841055 - New trial
Non-small cell lung cancer
Phase 2 Trial in Stage III NSCLC: Targeting DNA Repair with TRC102
This NCI-sponsored trial is evaluating TRC102 (a DNA repair inhibitor) in combination with standard pemetrexed-platinum therapy, radiation, and subsequent durvalumab in patients with non-squamous NSCLC, aiming to…
NCT05198830 - New trial
Breast cancer
Phase 1/2 Trial of BNT323 + BNT327 in Advanced HER2-Low/Ultralow/Null Breast Cancer
BioNTech is running a multi-site, open-label study evaluating the combination of BNT323—using DB-1303, a HER2-directed mAb ADC—and BNT327, a VEGFA-directed mAb, in patients with advanced breast cancer across a…
NCT06827236
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.